FOXO Technologies Inc.

FOXO Technologies, Inc. develops genetic sequencing technology artificial intelligence and bioinformatics tools. The company is headquartered in Minneapolis, MN.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOXO Technologies, Inc. develops genetic sequencing technology, artificial intelligence and bioinformatics tools. It operates through the FOXO Labs and FOXO Life segments. The FOXO Labs segment refers to the research and development and is commercializing proprietary epigenetic biomarker technology. The FOXO Life segment is involved in combining life insurance with a dynamic molecular health and wellness platform. The company was founded in 2020 and is headquartered in Minneapolis, MN.

MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced that its recently acquired subsidiary, Myrtle Recovery Centers, Inc. (“Myrtle”), has been granted two full licenses from the Tennessee Department of Mental Health and Substance Abuse Services, effective August 1, 2024, for 12 months. The first license authorizes the provision of services for alcohol and drug residential detoxification treatment, as well as alcohol and drug residential rehabilitation treatment. The second license authorizes the provision of services for non-residential office-based opiate treatment.

FOXO Technologies Subsidiary, Myrtle Recovery Centers, Receives Two Full Licenses from the Tennessee Department of Mental Health and Substance Abuse Services

Reaffirms commitment to regaining compliance with the NYSE American continued listing standards Reaffirms commitment to regaining compliance with the NYSE American continued listing standards

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

MINNEAPOLIS, MN, June 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), today announced that it has secured up to $2.8 million in Senior Notes from an institutional investor (“Investor”) to fund the previously announced acquisition of Myrtle Recovery Centers, Inc. as well as provide additional working capital to support the Company's growth strategy.

FOXO Technologies Inc. Secures Up to $2.8 Million in Senior Notes to Fund Previously Announced Acquisition of Myrtle Recovery Centers, Inc. and Provide Additional Working Capital

Acquisition expected to be synergistic with FOXO's epigenetic technology in community health and addiction recovery settings as well as contribute significant cash flow Acquisition expected to be synergistic with FOXO's epigenetic technology in community health and addiction recovery settings as well as contribute significant cash flow

FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc.

Foxo Technologies (NYSEMKT: FOXO ) stock is up on Friday after the epigenetic biomarkers technology company announced two acquisition deals. The first deal announced by Foxo Technologies is with Myrtle Recovery Centers.

Why Is Foxo Technologies (FOXO) Stock Up 55% Today?

BigBear.ai Holdings

Bullfrog AI Holdings Inc

Himax Tech

Inuvo

FiscalNote Holdings Inc

ParaZero Technologies Ltd

Penny stocks representing companies integrating AI into products and services hold particularly interesting upside. Penny Shares are known to move upward rapidly and the emergence of AI  continues to produce rapid gains.

7 AI Penny Stocks to Double Your Money: February 2024

Proposed Combination to Focus on Securing Our Nation's Supply to Critical Materials and Resources Proposed Combination to Focus on Securing Our Nation's Supply to Critical Materials and Resources

FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced the appointment of Francis Colt deWolf to the Company's Board of Directors. Mr. deWolf III brings over 20 years of experience in the financial services Sector. He currently serves as President of Colt Capital LLC, a Florida-based company, whose principal activities focus on advising emerging market companies on private and public financing strategies. Prior to founding Colt Capital LLC, M.

FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced it has formalized its collaboration with KR8.ai Inc. (“KR8”) and secured the exclusive license to KR8's AI-based software to support the development and commercial launch of its new health and wellness offering - the VITHAR™ AI Health Coach. As previously announced, the Company is in the process of launchi.

FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a business update on the planned commercial rollout of its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach. The Company also expects to report its financial results for the three and nine months ended September 30, 2023, which the Company anticipates will reflect a reduction in losses in excess of $10 million.

FOXO Technologies On Track to Commence Commercial Rollout of VITHAR™ AI Health Coach in Early 2024

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, announced that on November 21, 2023, it received a notice from NYSE Regulation stating that the Company is not in compliance with the continued listing standards of the NYSE American (the “Exchange”) under the timely filing criteria set forth in Section 1007 of the NYSE American Company Guide (the “Company Guide”). The non-compliance res.

FOXO Technologies Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a reminder that it will host a webinar on Friday, November 10, 2023, at 10 AM Eastern Time, which will be available on the Company's website at https://foxotechnologies.com/. The Company plans to unveil its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, which is designed to intake health data from available.

FOXO Technologies Provides Reminder for Webinar to be Held Today, November 10th at 10 AM Eastern Time, to Unveil VITHAR™ AI Health Coach

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today announced that it will host a webinar on Friday, November 10, 2023, at 10 AM Eastern Time, which will be available on the Company's website at https://foxotechnologies.com/. The Company plans to unveil its new direct-to-consumer (DTC) app, the VITHAR™ AI Health Coach, which is designed to intake health data from available APIs alre.

FOXO Technologies to Unveil VITHAR™ AI Health Coach; Schedules Webinar for Friday, November 10th at 10 AM Eastern Time

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today announced that it expects its Class A common stock (the “Common Stock”) to resume trading today, November 7, 2023, in connection with a 1-for-10 reverse stock split of its issued and outstanding shares of Common Stock to regain compliance with the continued listing requirements, as set forth in Section 1003(f)(v) of the NYSE Americ.

FOXO Technologies Expects Class A Common Stock to Resume Trading, Today, November 7, in Connection with 1-for-10 Reverse Stock Split

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced plans for a new subscription-based, direct-to-consumer product offering that will provide personalized health and wellness recommendations, by combining: (i) FOXO's machine learning models to analyze epigenetic biomarkers; (ii) the Company's expertise and algorithms correlating epigenetic analysis with hea.

FOXO Technologies Unveils Plans for New Direct-to Consumer Offering Combining the Company's Epigenetic Data with the Power of AI

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's Class A common stock, par value $0.0001 (the “Common Stock”). The reverse stock split will become effective at 4:01pm ET on November 6, 2023. The Common Stock is expected to begin trading on a split-adjusted basis on t.

FOXO Technologies Inc. Announces Reverse Stock Split

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announces it has completed its strategic review, following recent management changes, and provided a business update on the Company's progress and plans. Mark White, Interim CEO of FOXO Technologies, stated, “Since taking the helm just over a month ago, FOXO's new management team has initiated a significant restruct.

FOXO Technologies Completes Strategic Alternatives Review and Outlines Latest Progress Executing Corporate Strategy

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced that the United States Patent & Trademark Office (USPTO) has provided an Issue Notification for a key patent utilizing a machine learning model trained to determine a biochemical state and/or medical condition using DNA epigenetic data to enable the commercialization of epigenetic biomarkers. Previousl.

FOXO Technologies Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today provided a letter to shareholders from the Company's newly appointed interim CEO, Mark White. “While this has been a turbulent period for the Company, I am honored to take the helm of FOXO Technologies. Before accepting this role, I undertook a comprehensive review of the technology and market potential for FOXO's p.

FOXO Technologies™ Interim CEO Mark White Provides Letter to Shareholders Outlining New AI-Enabled Direct-to-Consumer Strategy and Immediate Expense Reductions

MINNEAPOLIS, Minn.--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE™, has engaged Atrio Insurance/Singular Insurance Brokerage, an insurance brokerage general agency offering products and specialty programs throughout the United States, to sell.

FOXO Technologies Announces Agreement With Atrio Insurance

MINNEAPOLIS--(BUSINESS WIRE)--On August 29, 2023, FOXO Technologies Inc. (the “Company”) (NYSEAM: FOXO) received a letter (the “Letter”) from NYSE American LLC (“NYSE American”) stating that NYSE American reviewed and accepted the plan of compliance (the “Plan”) submitted by the Company in response to NYSE American's June 12, 2023 notice (the “Notice”) informing the Company that it was not in compliance with the continued listing standards set forth in Section 1003(a)(i) of the NYSE American Co.

FOXO Technologies Inc. Announces NYSE American Acceptance of Compliance Plan

MINNEAPOLIS--(BUSINESS WIRE)--On August 16, 2023, FOXO Technologies Inc. (NYSEAM: FOXO) (the “Company”) received a second written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that it is not in compliance with the continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company's Class A common stock was selling for a low price per share for a substantial period of time, which NYSE American d.

FOXO Technologies Inc. Announces Receipt of Second Notice of Non-Compliance from NYSE American

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity. In collaboration with DataRobot, the leader in Value-Driven AI, FOXO has successfully harnessed the powers of predictive AI and high-throughput automation to estimate factors associated wi.

FOXO Technologies™ Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter ended June 30, 2023. “I am very proud of our accomplishments during the second quarter,” said Tyler Danielson, interim CEO and Chief Technology Officer of FOXO. “In addition to streamlining our capital structure, we continued to advance our growth initiatives through product expansion and scientific.

FOXO Technologies™ Announces Second Quarter 2023 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in epigenetic biomarker discovery and commercialization, today announced that it will report financial results for the second quarter ended June 30, 2023 after market closes on Thursday, August 10, 2023. Management will host a conference call to discuss second quarter 2023 results and recent business highlights at 3:15 p.m. Central time on Thursday, August 10, 2023. During the call, FOXO management will provide prepa.

News for FOXO Technologies Inc. Stock (FOXO)